INmune Bio advances CORDStrom in UK, secures FDA alignment for XPro1595 Alzheimer's program

Inmune Bio, Inc.

Submitted CORDStrom pre-submission package to UK MHRA for RDEB; targets full MAA filing mid-summer 2026.
FDA aligns on integrated Phase 2b/3 design for XPro1595 in early Alzheimer's; CDR-SB sole primary endpoint.
Phase 2b portion to enroll ~300 patients over 9 months; full program ~1,000 participants over 18 months.
Biomarker-driven enrichment strategy (hsCRP, ESR, HbA1c, APOE4) accepted; exploratory non-enriched cohort included.
CORDStrom also benefits from reauthorized Rare Pediatric Disease PRV program through 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.